Alopecia World
www.alopeciaworld.com
Xeljanz (Tofacitinib Citrate): My experience on the trial
I have received a lot of interest from others on here in my involvement with the Xeljanz trials at Yale.
I thought it would be nice for everyone if I documented my progress on here.
Xeljanz is a Jak3 inhibitor and is believed to work with alopecia by turning off the distress signal relayed by the hair follicle to the attacking immune system which is the cause of the hairs falling out. Xeljanz comes in a strength of 5mg per pill and a full box contains 60 tablets. The recommended dosage for arthritis is 1 tablet in the morning and another in the evening each day.
The trial is set in a series of stages and there are requirements before participating. These include monthly visits and blood tests every 2 weeks. Dr Brett King is absolutely fantastic and is an inspiration to me. His positivity and enthusiasm gives me the much needed hope I have craved for over a decade. I have been put on a low dose to start with which is 1 tablet every other day. My dosage has now been increased to 1 tablet every day and next month it could be increased to 2 tablets per day depending on the results.
I have completed my first month and have already noticed my alopecia has stabilised . I have not lost any existing hairs. In addition to this I have seen little hairs growing in my chest area as well as eyebrows. Fingers crossed! To date, I have experienced no side effects.
-----------------------------
AW: Other discussions on Xeljanz / Tofacitinib
https://alopeciaworld.com/main/search/search?q=Tofacitinib
Replies to This Discussion
-
Permalink Reply by asp2014 on
-
hey ADML,
Just curious, why do you think it would be better than Xeljanz and Jakavi for treating alopecia?
-
Permalink Reply by AlopeciaDestroyedMyLife on
-
Hey asp,
As long as it's cheaper , has a better safety profile and can regrow hair. It is likely to overtake the other JAK inhibitors for alopecia.
Having a better safety profile would mean there is more of a chance of it being approved in all countries for treatment rather than just some countries like Xeljanz is. In addition if it was cheaper as well it would give many more people the opportunity to seek treatment.
-
-
Baricitinib is looking like a very promising possibility for AA/ AU. Once the Columbia results come out on Jakavi, I think we will have a better picture of what a JAK 2 inhibitor can do for us. If this drug proves to be just as effective as a JAK 3 with a cheaper price tag and significantly better safety profile, it will be the dominate winner.
Things are getting more and more exciting now that there are other classes of drugs to look at for our condition outside of steroids.
Luckily we are in an age where technology is exploding exponentially and medical research is benefiting from it.
-
-
Wow this is really exciting! Thank you so much for sharing y yules. I am one month into the xeljanz and was planning on staying on it for 6-8 months (that's about what makes sense for me financially) and then crossing my fingers that the FDA will approve it so i can go through my insurance.
The barcicitinib is significantly cheaper... I am wondering if anyone currently on xeljanz is considering switching over or if you are going to see the xeljanz through..? I know that its relatively new but it seems like the same principle as xeljanz.
-
-
Hope it goes well Julie! I think jak inhibitors is clearly answer to our problems. If you are keen on looking for any aternatives and are based in the US I think Eli Lilly is doing few clinical trials at the moment on Baricitinib(it's in 3d phase of trials), maybe worth contacting them, i dont think any cost is involved. Unfortunately for me there are no trials in the UK at the moment.There is another drug, that caught my attention, it went into second phase of trials in Belgium called Filgotinib which is even more promising as it is selective jak 1 inhibitor but we are probably about few years away from it being approved by fda.
-
-
I have been doing research on barcicitinib and cannot find it available for sale. Where are you guys seeing prices and information? Just curious, thanks
-
-
Hi Justin it is not available for sale as it is still in trials, 3d phase. Results should be in by the end of the year...
-
Permalink Reply by DJ88 on
-
So are they like making for alopecia mind or is it for other things but happens to work for alopecia?
-
-
It is for RA but will likely work for alopecia (one study has shown it to work for AA). The genome studies of 2010 has shown where RA and alopecia share many of the same markers. This is a huge plus for us because, as we all know, research and drug studies are limited with our disease. This allows us to "piggy-back" on the new RA drugs and not wait for something to be developed for us from scratch. With that said, this new drug will likely still be expensive but have a much higher likelihood of being FDA/ insurance approved...thus reducing our personal out-of-pocket expense. This is all due to the better safety profile.
-
-
Most market research articles indicate that baricitinib will be introduced to the market in 2023, if I'm correct (?), and filgotinib has only completed phase 2B
Their availability seems a pretty long way off, especially for people who do not have access to Jakavi in the meantime :-/ (although the improved side effect profile is exciting of course).
What really bothers me though is that we don't see any of the promised studies with topical jaks for alopecia happening (correct me if I'm wrong)...As far as I know, Christiano and Clynes hold the patent for their use in alopecia and their further development for treatment of psoriasis is not pursued by any pharma company.
-
-
so awesome for you - I hope the trials prove successful..
Any trials in Australia?
-
-
I found this on Instagram. Is this anyone here???? These results, if true, are some of the most promising. It has to be someone on here.....apparently this is 7 weeks on Xeljanz
http://instagram.com/p/1LbMcFEhJC/
© 2024 Created by Alopecia World.
Powered by
